starting

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK(lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease Under Fast Track Status

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from…

3 months ago

Zhejiang-based GNMI Expands Overseas: Hangzhou Becomes a New Starting Point for the China-German Industrial Synergies

Hangzhou, China, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Against the backdrop of West Lake, where the reflections of water meet…

3 months ago